Cargando…
COVID-19 patient serum less potently inhibits ACE2-RBD binding for various SARS-CoV-2 RBD mutants
As global vaccination campaigns against SARS-CoV-2 proceed, there is particular interest in the longevity of immune protection, especially with regard to increasingly infectious virus variants. Neutralizing antibodies (Nabs) targeting the receptor binding domain (RBD) of SARS-CoV-2 are promising cor...
Autores principales: | Junker, Daniel, Dulovic, Alex, Becker, Matthias, Wagner, Teresa R., Kaiser, Philipp D., Traenkle, Bjoern, Kienzle, Katharina, Bunk, Stefanie, Struemper, Carlotta, Haeberle, Helene, Schmauder, Kristina, Ruetalo, Natalia, Malek, Nisar, Althaus, Karina, Koeppen, Michael, Rothbauer, Ulrich, Walz, Juliane S., Schindler, Michael, Bitzer, Michael, Göpel, Siri, Schneiderhan-Marra, Nicole |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9062870/ https://www.ncbi.nlm.nih.gov/pubmed/35505068 http://dx.doi.org/10.1038/s41598-022-10987-2 |
Ejemplares similares
-
Immune response to SARS-CoV-2 variants of concern in vaccinated individuals
por: Becker, Matthias, et al.
Publicado: (2021) -
NeutrobodyPlex—monitoring SARS‐CoV‐2 neutralizing immune responses using nanobodies
por: Wagner, Teresa R, et al.
Publicado: (2021) -
Biparatopic nanobodies protect mice from lethal challenge with SARS‐CoV‐2 variants of concern
por: Wagner, Teresa R, et al.
Publicado: (2021) -
Antibody Binding and Angiotensin-Converting Enzyme 2 Binding Inhibition Is Significantly Reduced for Both the BA.1 and BA.2 Omicron Variants
por: Junker, Daniel, et al.
Publicado: (2022) -
Predictors of RBD progression and conversion to synucleinopathies
por: de Natale, Edoardo Rosario, et al.
Publicado: (2022)